Independent Research Analysts Give Bayer (BAYN) a €120.00 Price Target

Independent Research set a €120.00 ($142.86) price target on Bayer (FRA:BAYN) in a report issued on Friday. The brokerage currently has a neutral rating on the healthcare company’s stock.

Several other research firms have also weighed in on BAYN. Citigroup set a €130.00 ($154.76) target price on shares of Bayer and gave the company a buy rating in a report on Thursday, October 5th. UBS Group set a €125.00 ($148.81) target price on shares of Bayer and gave the company a buy rating in a report on Monday, November 6th. Sanford C. Bernstein set a €126.00 ($150.00) target price on shares of Bayer and gave the company a buy rating in a report on Friday, October 6th. Deutsche Bank set a €124.00 ($147.62) target price on shares of Bayer and gave the company a buy rating in a report on Friday, October 27th. Finally, Baader Bank set a €140.00 ($166.67) target price on shares of Bayer and gave the company a buy rating in a report on Wednesday, September 20th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and fourteen have given a buy rating to the company. The company has a consensus rating of Buy and a consensus price target of €122.33 ($145.63).

Bayer (FRA:BAYN) traded down €0.62 ($0.74) during trading hours on Friday, hitting €104.86 ($124.83). 2,223,938 shares of the stock traded hands. The stock has a market cap of $86,730.00 and a price-to-earnings ratio of 28.11. Bayer has a 52-week low of €99.69 ($118.68) and a 52-week high of €123.82 ($147.40).

ILLEGAL ACTIVITY WARNING: “Independent Research Analysts Give Bayer (BAYN) a €120.00 Price Target” was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.com-unik.info/2018/01/13/independent-research-analysts-give-bayer-bayn-a-120-00-price-target.html.

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Analyst Recommendations for Bayer (FRA:BAYN)

What are top analysts saying about Bayer? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bayer and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit